Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY -0.07% 59.09 Delayed Quote.5.01%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
05/25EISAI : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Provide Update on Supple..
AQ
05/25MERCK AND : Eisai And Merck Provide Update on Supplemental New Drug Application ..
AQ
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/25MERCK AND : Eisai And Merck Provide Update on Supplemental New Drug Application ..
PR
05/25MERCK AND : Eisai and Merck Provide Update on Supplemental New Drug Application ..
PU
05/24MERCK AND : Announces Third-Quarter 2018 Dividend
AQ
05/24MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
AQ
05/24Keytruda improves survival in first-line squamous NSCLC
AQ
05/23Why the world needs more than one Ebola vaccine
RE
05/23MERCK AND : KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival an..
BU
More news
News from SeekingAlpha
01:54pBristol-Myers Squibb Is One Stock That You Should Not Ignore 
05/26VENTURE CAPITAL DEALS OF THE WEEK : Ant Financial's $200M Motion Sensor Bet 
05/26MINING ASCO 2018'S GOLD, PART 4 : Radiation Glows In Breast And Brain 
05/26Know When To Hold 'Em 
05/25Xeris Pharmaceuticals on deck for IPO 
Financials ($)
Sales 2018 42 112 M
EBIT 2018 13 641 M
Net income 2018 7 201 M
Debt 2018 15 704 M
Yield 2018 3,30%
P/E ratio 2018 22,70
P/E ratio 2019 15,24
EV / Sales 2018 4,15x
EV / Sales 2019 3,95x
Capitalization 159 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,1 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY5.01%158 970
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
AMGEN2.33%117 942